The risk of gastric cancer in carriers of CHEK2 mutations
- 8 January 2013
- journal article
- research article
- Published by Springer Nature in Familial Cancer
- Vol. 12 (3) , 473-478
Abstract
CHEK2 is a tumor suppressor gene whose functions are central to the induction of cell cycle arrest and apoptosis following DNA damage. Mutations in CHEK2 have been associated with cancers at many sites, including breast and prostate cancers, but the relationship between CHEK2 and gastric cancer has not been extensively studied. In Poland, there are four known founder alleles of CHEK2; three alleles are protein truncating (1100delC, IVS2G>A, del5395) and the other is a missense variant (I157T). We examined the frequencies of four Polish founder mutations in the CHEK2 gene in 658 unselected gastric cancer patients, in 154 familial gastric cancer patients and in 8,302 controls. A CHEK2 mutation was seen in 57 of 658 (8.7 %) unselected patients with gastric cancer compared to 480 of 8,302 (5.8 %) controls (OR 1.6, p = 0.004). A CHEK2 mutation was present in 19 of 154 (12.3 %) familial cases (OR = 2.3, p = 0.001). The odds ratio for early onset (p = 0.01), than for cases diagnosed at age of 50 or above (OR 1.4, p = 0.05). Truncating mutations of CHEK2 were associated with higher risk (OR = 2.1, p = 0.02) than the missense mutation I157T (OR = 1.4, p = 0.04). CHEK2 mutations predispose to gastric cancer, in particular to young-onset cases.Keywords
This publication has 26 references indexed in Scilit:
- Risk of Breast Cancer in Women With a CHEK2 Mutation With and Without a Family History of Breast CancerJournal of Clinical Oncology, 2011
- Family history and the risk of gastric cancerBritish Journal of Cancer, 2009
- Constitutional CHEK2 mutations are associated with a decreased risk of lung and laryngeal cancersCarcinogenesis, 2008
- Founder and Recurrent CDH1 Mutations in Families With Hereditary Diffuse Gastric CancerJAMA, 2007
- Germline CHEK2 mutations and colorectal cancer risk: different effects of a missense and truncating mutations?European Journal of Human Genetics, 2006
- A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancerJournal of Medical Genetics, 2006
- A CHEK2 Genetic Variant Contributing to a Substantial Fraction of Familial Breast CancerThe American Journal of Human Genetics, 2002
- Mutation analysis of the CHK2 gene in breast carcinoma and other cancersBreast Cancer Research, 2002
- Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitroProceedings of the National Academy of Sciences, 2000
- Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathwayOncogene, 1999